Zoll Medical Acquires TherOx

June 18, 2019—Zoll Medical Corporation, an Asahi Kasei Group Company, announced it has acquired TherOx, Inc., a privately held company based in Irvine, California. TherOx is focused on improving the treatment of acute myocardial infarction (AMI) and markets systems to deliver the company's proprietary SuperSaturated Oxygen (SSO2) therapy.

According to Zoll Medical, TherOx's SSO2 therapy, which received FDA approval in April 2019, has been shown to reduce infarct size after primary percutaneous coronary intervention (PCI) with stenting in patients with left anterior descending ST-segment elevation MI.

Immediately after a coronary artery has been opened by PCI, SSO2 therapy delivers a one-time, 60-minute infusion of the patient’s super-oxygenated blood to the targeted ischemic area of the heart through a small catheter. This treatment improves microvascular flow, then restores heart tissue to normal oxygen levels. SSO2 therapy is aligned with current guidelines for interventional cardiology procedures, advised the company.